Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin [Internet]. 2024 Jul. 23 [cited 2026 Apr. 12];8(4):s406. Available from: https://skin.dermsquared.com/skin/article/view/2854